ArticleCurrent medicinal chemistry2025
Proteomics Analysis of Five Potential Plasma-derived Exosomal Biomarkers for Acute Myocardial Infarction.
Article in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Proteomics-based machine learning model for predicting secondary infection in HBV-related liver failure.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
aimsThis study was to explore the relationship between plasma exosomes and Acute myocardial infarction (AMI).
backgroundAcute myocardial infarction (AMI) is one of the most common cardiovascular complications. Recent studies have shown that exosomes play a crucial role in the development and progression of cardiovascular diseases. However, there is a lack of relevant research on the relationship between plasma exosomes and AMI.
objectiveThis study was designed to explore the relationship between plasma exosomes and AMI.
methodsThis retrospective study collected the basic clinical data of patients with AMI (n = 10), stable angina pectoris (SAP, n = 10), and noncoronary heart disease (CON, n = 10) at the Department of Cardiovascular Medicine at Taizhou Hospital (Zhejiang, China, 2021.01 to 2021.12). Proteomics was used to systematically screen the differential proteins of plasma exosomes in patients with clinical AMI, SAP, and CON. Then, the results were further verified using parallel reaction monitoring (PRM).
resultsFive of all the differentially expressed proteins (DEPs) were quantified by PRM. Compared with the CON group, heparin cofactor 2 (SERPIND1), mannan-binding lectin serine protease 1 (MASP1), ficolin-2 (FCN2), and α1-Microglobulin/bikunin precursor (AMBP) were upregulated in patients with AMI and SAP, with a higher expression in AMI than in SAP. Additionally, human leukocyte antigen (HLA-C) was downregulated in both exosomes and plasma.
conclusionThe expression of four plasma exosome biomarkers in AMI and SAP patients was higher than that in noncoronary heart disease (NCHD) patients. HLA-C was downregulated in both exosomes and plasma, showing a potential to serve as a new candidate target for the detection and therapy of AMI.
Indexed as
Identifiers
39754756What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.